by VICO Therapeutics | Apr 3, 2023 | Press Release
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
by VICO Therapeutics | Oct 3, 2022 | Management, Press Release
Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
by VICO Therapeutics | Aug 4, 2022 | Management, Press Release
LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
by VICO Therapeutics | Mar 1, 2022 | Rare Disease Day
BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
by VICO Therapeutics | Jul 29, 2021 | Press Release
Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...